Charles Schweizer

A phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of IMGS-001 in patients with relapsed or refractory advanced solid tumors.

David S. Hong, Shiraj Sen, Charles Schweizer, Amanda Sanders et autres

TPS2686 Background: IMGS-001 is a fully human, dual specific immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds both PD-L1 and PD-L2, silencing the entire PD-1 inhibitory circuit, with an engineered fragment crystallizable (Fc) region designed to induce robust antibody-dependent cell-mediated cytotoxicity (ADCC) …

us (code pays fourni par la source)

Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC)

Sarah E. Hoffe, Jessica M. Frakes, Todd A. Aguilera, Brian G. Czito et autres

us, ca (code pays fourni par la source)

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer

Kenneth H. Kim, Susan C. Weil, Ronald D. Alvarez, Danijela Jelovac et autres

Farletuzumab is a humanized monoclonal antibody that binds to folate receptor alpha, over-expressed in epithelial ovarian cancer (EOC) but largely absent in normal tissue. Previously, carboplatin plus pegylated liposomal doxorubicin showed superior progression-free survival and an improved therapeutic index compared with carboplatin/paclitaxel …

us (code pays fourni par la source)

Farletuzumab, a monoclonal antibody directed against folate receptor alpha, shows no evidence of teratogenicity in cynomolgus monkeys

Tomoyuki Moriyama, Dai Kakiuchi, Luigi Grasso, David Hutto et autres

us, jp (code pays fourni par la source)

CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients

Nicholas C. Nicolaides, Charles Schweizer, Elizabeth B. Somers, Wenquan Wang et autres

The tumor-shed antigen CA125 has recently been found to bind certain monoclonal antibodies (mAbs) and suppress immune-effector mediated killing through perturbation of the Fc domain with CD16a and CD32a Fc-γ activating receptors on immune-effector cells. Amatuximab is a mAb targeting mesothelin whose …

us (code pays fourni par la source)

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma

Sandra P. D’Angelo, Omid Hamid, Ahmad A. Tarhini, Dirk Schadendorf et autres

us, de (code pays fourni par la source)

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

Axel Grothey, Jonathan Strosberg, Lindsay A. Renfro, Herbert I. Hurwitz et autres

Abstract Purpose: The purpose of this study was to evaluate the safety and efficacy of ontuxizumab (MORAb-004), a monoclonal antibody that interferes with endosialin (tumor endothelial marker-1) function, in patients with chemorefractory metastatic colorectal cancer and to identify a responsive patient population …

us (code pays fourni par la source)

Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement

J. Bradford Kline, Rina Kennedy, Earl F. Albone, Qimin Chao et autres

// James Bradford Kline 1 , Rina P. Kennedy 1 , Earl Albone 1 , Qimin Chao 1 , Shawn Fernando 1 , Jennifer M. McDonough 1 , Katherine Rybinski 1 , Wenquan Wang 1 , Elizabeth B. Somers 1 , Charles …

us (code pays fourni par la source)

Abstract 644: CA125/MUC16 suppresses antibody-dependent cellular cytotoxicity of IgG1-based therapies via perturbation of antibody Fc-Receptor engagement on immune effector cells

J. Bradford Kline, Rina Kennedy, Shawn Fernando, Jennifer McDonough et autres

Abstract Background: Human cancers employ a number of mechanisms to evade host immune responses. Here we report the effects of the tumor-shed antigen CA125 (MUC16) on suppressing IgG1-mediated antibody-dependent cellular cytotoxicity (ADCC). This evidence stems from prespecified subgroup analysis of an 1100 …

us (code pays fourni par la source)

Abstract 1743: Comprehensive genomic characterization of a large cohort of platinum-sensitive, high-grade serous ovarian cancer (HGSOC) FFPE specimens

Brian C. Haynes, Marie E. Fahey, Darcy Myers, Diane Ilsley et autres

Abstract Introduction: Ovarian cancer is a leading cause of cancer related death in women. A comprehensive genomic characterization of platinum-sensitive tumors is required to further refine the definition of molecular subtypes and identify targeted therapies for this patient population. To this end …

us (code pays fourni par la source)

Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer

Daniel J. O’Shannessy, Katie Bendas, Charles Schweizer, Wenquan Wang et autres

us (code pays fourni par la source)

FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125

Wenquan Wang, Elizabeth B. Somers, Erin N. Ross, J. Bradford Kline et autres

Farletuzumab is a humanized monoclonal antibody that binds to folate receptor alpha and elicits an anti-tumor response via immune effector activity. Recent studies from a global phase 3 trial in ovarian cancer patients treated with carboplatin/taxane plus farletuzumab found that the tumor-produced …

us (code pays fourni par la source)